drugset / Trial / NCT00050414
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Phase 2
Completed
147 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced ovarian cancer.
Timeline
- Start
- 2002-10
- Primary completion
- —
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | 0.58 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 10 mg | Intravenous |